Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?
about
Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liverStereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytesMarine nucleosides: structure, bioactivity, synthesis and biosynthesisGlucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomesDiclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolitesMechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.Separatory determination of diastereomeric ibuprofen glucuronides in human urine by liquid chromatography/electrospray ionization-mass spectrometry.Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice.The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling.Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!The pharmacokinetics of ketorolac enantiomers following intramuscular administration of the racemate.Studies on the renal excretion of the acyl glucuronide, phenolic glucuronide and sulphate conjugates of diflunisalThe pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidineGenetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.Contribution of the human kidney to the metabolic clearance of drugs.Nephrotoxicity induced by C- and N-arylsuccinimides.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Evidence for covalent binding of acyl glucuronides to serum albumin via an imine mechanism as revealed by tandem mass spectrometry.Characterization of the acyl-adenylate linked metabolite of mefenamic AcidDrug metabolite profiling and elucidation of drug-induced hepatotoxicity.Characterization of WY 14,643 and its Complex with Aldose Reductase.Current concepts of mechanisms in drug-induced hepatotoxicity.CPY3A4-mediated α-hydroxyaldehyde formation in saquinavir metabolism.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Assessment of reactive metabolites in drug-induced liver injury.The generation, detection, and effects of reactive drug metabolites.Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology.Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases.Specific targets of covalent drug-protein interactions in hepatocytes and their toxicological significance in drug-induced liver injury.Drug metabolism: from experiments to regulatory aspects.Synthesis and mass-spectrometric characterization of human serum albumins modified by covalent binding of two non-steroidal anti-inflammatory drugs: tolmetin and zomepirac.Reversible binding of tolmetin, zomepirac, and their glucuronide conjugates to human serum albumin and plasma.Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil.Evaluation of glucuronide metabolite stability in dried blood spots.Acylglucuronide in alkaline conditions: migration vs. hydrolysis.Hepatic covalent adduct formation with zomepirac in the CD26-deficient mouse.Stereospecific pH-dependent degradation kinetics of R- and S-naproxen-beta-l-O-acyl-glucuronide.
P2860
Q24304203-E4D31D60-EFB1-403E-8644-BF86FA2EA507Q24650448-B662383D-A7AF-46D4-99E2-CB448D7B9455Q26995473-04B2C045-B85F-44C4-9C54-B9AE9FE9BAAEQ28354181-AD43EDCE-9792-4B6F-A7AF-B96B6539B3B0Q28475945-3500C8D9-990F-4951-A60E-A7161E1551BFQ31147512-B99298F6-BCC2-4331-BB56-2627E3C46AE3Q31949677-7FF84DCE-FAD3-40A2-BDAC-615387DE248BQ33742730-5E9A0CFF-9962-4062-A05A-A0CA85250927Q34086259-A78A3325-1C6B-48E2-932C-E9E549AA6E33Q34289184-BA559508-7D8F-424E-9EEF-00A3ED093C53Q34345976-1A08C70D-C8DF-42D5-9D7C-49B91059D075Q34403802-F43B3B92-608B-4DB4-9597-441077CD8E0DQ34404263-1D81C7F7-F714-40D1-877A-8CE708268E83Q34638720-AE08736B-6388-41F7-B774-809EDB10EC38Q34702576-65C1FAA5-D88E-45C6-889C-D62214FA7892Q35027930-F11D904E-409B-4208-9B35-96C988DDAEAFQ35653360-1698D2A0-F362-43FE-8566-FA620D1C8896Q35889175-F31AEC5C-C031-4ECE-933F-4692D28B876DQ36061821-B33B299D-A994-4BC2-B978-D2F891D27873Q36264378-3EC7F976-7CFE-4E44-9946-DFDDFE62E9A7Q36765756-200B5B89-CEBB-4385-A16A-BF5FC2AA9341Q36835826-3DF1D866-344A-4C4B-8DE8-D9B6919EC4C4Q37323900-669C2764-7F48-4A03-B18A-452A1BC71DAEQ37394799-810EA3CF-5F5B-4ACE-9FE1-BC4F4D31EB20Q37550673-C7A665B4-AF6A-4F2D-A730-C979CA2C6E22Q37638755-5E45CCC3-49FB-4355-ACB6-5F5A210ED51AQ37964578-E1AA765E-AB37-4199-BBD2-1304C5E3827DQ38054629-74A33A65-10D9-488C-ADDE-6EFA4ED89E6EQ39061191-D9B0D886-C1B1-4756-A330-D108FF4C6AC6Q40422942-813967D0-5273-4EDD-9750-B3C4CB189C83Q40539522-AC66437F-143E-4EFE-A1EF-6F48E2AF6B4AQ40817414-B29C42BC-28EB-4575-B301-E34F25B45185Q41570003-2E96AE37-D3BB-4350-AF11-916F38BCA23CQ42107928-3D954385-1830-4363-8849-B6C08BDED157Q42283470-EDF73888-08A2-44F0-905D-A6EE32325886Q43189802-5B4A3ADD-DC30-4D1B-8EF1-23F9ACADAFE0Q43465450-BB6C0EDA-CF9D-4CEF-9E02-E0DF4F34C4D9Q43665617-DD9BE5C9-569B-4ECF-BD84-6BF3AC51F3EBQ43918476-87FFFCA6-32E5-460C-B5BC-44445CABBCD3Q43968170-188CD51D-5BCD-4828-97CA-FB8FCCAFD3CA
P2860
Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@ast
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@en
type
label
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@ast
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@en
prefLabel
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@ast
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@en
P2860
P1476
Acyl glucuronides revisited: i ...... as a detoxification mechanism?
@en
P2093
Spahn-Langguth H
P2860
P356
10.3109/03602539208996289
P407
P577
1992-01-01T00:00:00Z